Skip to content Skip to sidebar Skip to footer
0 items - $0.00 0

Research & Science

HomeResearch & Science
Close

Research & Science

An overview of the most exciting current frontiers in Parkinson’s disease research — from alpha-synuclein-targeting therapies and biomarker development to gene therapy, stem cells, and artificial intelligence applications.

15.1 The Disease-Modification Imperative

Despite remarkable advances in symptomatic treatment, no disease-modifying therapy — one that slows, stops, or reverses underlying neurodegeneration — has yet been approved for PD. This is the defining unmet need in the field. The challenge is formidable: by the time motor symptoms emerge, 50–70% of nigral dopaminergic neurons are already lost, and the heterogeneous, slowly progressive nature of PD makes clinical trial design extremely difficult.

15.2 Alpha-Synuclein Targeting Strategies

Alpha-synuclein (αSyn) is the central protein in PD pathology and the primary therapeutic target. Multiple strategies are under active clinical investigation:

  • Passive immunotherapy (monoclonal antibodies): Antibodies targeting extracellular and intracellular αSyn. Prasinezumab (Roche/Prothena) is the most advanced, completing Phase II; results showed slowing in a biomarker-defined subgroup. Multiple other antibodies (cinpanemab, BIIB054) were negative in Phase II. The field is refining target epitopes and patient selection.
  • Active immunotherapy (vaccines): PD01A and PD03A (AFFiRiS) target specific αSyn epitopes to stimulate antibody production. Phase I data showed safety and immunogenicity. UB-312 (United Neuroscience) is in Phase I.
  • ASO and siRNA (gene silencing): Antisense oligonucleotides (ASOs) targeting SNCA mRNA to reduce αSyn production. Ionis/AstraZeneca’s BIIB101 demonstrated effective CNS delivery and αSyn reduction in Phase Ib; Phase II underway. Particularly relevant for SNCA-duplication/triplication patients.
  • Small molecule inhibitors of αSyn aggregation: Multiple compounds targeting the aggregation cascade, including anle138b (MODAG), which has completed Phase I and is entering Phase II in MSA and PD.

15.3 LRRK2 Inhibitors

LRRK2 kinase inhibitors represent the most advanced genetically-targeted therapeutic strategy in PD. Denali Therapeutics’ BIIB122 (DNL201/DNL151) has demonstrated effective LRRK2 kinase inhibition, reduced LRRK2 biomarkers, and an acceptable safety profile in Phase I/II studies in both LRRK2 mutation carriers and idiopathic PD. A Phase III program (LIGHTHOUSE trial) is underway. Neurimmune and Sanofi also have LRRK2 programs in clinical development. The relevance to sporadic PD — where LRRK2 activity may be elevated beyond mutation carriers — expands the potential therapeutic population substantially.

15.4 GBA1-Targeted Therapies

GBA1 mutations (encoding glucocerebrosidase) are the most common genetic risk factor for PD. Several GBA1-targeted strategies are in clinical trials: venglustat (Sanofi; glucosylceramide synthase inhibitor) and ambroxol (GBA1 chaperone) completed Phase II trials; results have been mixed but the field continues to refine patient selection. LTI-291 (Lysosomal Therapeutics) — a direct GBA1 activator — and PR001/LYS-SAF302 (Prevail/Eli Lilly, Sanofi; AAV-GBA1 gene therapy) are in Phase II/III trials.

15.5 Biomarkers — The Foundation of Future Trials

The development of reliable PD biomarkers is transforming the field, enabling prodromal detection, accurate patient stratification, and objective monitoring of treatment response. Breakthrough developments include:

  • Alpha-synuclein seed amplification assay (αSyn-SAA): Detects misfolded αSyn in CSF, skin, and nasal brushings with ~88% sensitivity and 96% specificity. Published in The Lancet Neurology (Iranzo et al., 2021) and being integrated into clinical trials as inclusion criterion and progression biomarker.
  • Neurofilament light chain (NfL): Serum NfL correlates with neurodegeneration rate and distinguishes typical PD from atypical parkinsonism.
  • Imaging biomarkers: Neuromelanin-sensitive MRI, iron-sensitive MRI (nigrosome-1 “swallow tail” sign), PET tracers for αSyn, tau, inflammation, and mitochondrial dysfunction.
  • Digital biomarkers: Wearable sensors (accelerometers, gyroscopes) measuring gait, tremor, and activity in real-world settings with high sensitivity to change; smartwatch-based tremor and gait assessment apps are entering clinical trials as outcome measures.

15.6 Artificial Intelligence & Digital Health

AI and machine learning are transforming PD research and care across multiple domains: automated diagnosis from wearable sensor data (voice analysis, gait assessment); drug discovery acceleration through molecular docking simulations and protein structure prediction (AlphaFold); early detection from retinal imaging; and personalized treatment optimization from large observational cohort data. The Parkinson’s Progression Markers Initiative (PPMI) — a longitudinal, multicenter biomarker study with over 1,000 participants — has generated one of the world’s largest open-access neurodegeneration datasets, freely available to researchers globally.

References: Brundin et al. (2023) Nature Reviews Neuroscience; Iranzo et al. (2021) Lancet Neurology; Marek et al. (2011) Progress in Neurobiology (PPMI).

Navigation: ← Caregivers | Resources →